USPTO serial 90620821
MEDICAGO UNLEASH THE POWER OF PLANTS
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Oct 11, 2022
- Examiner
- DAVIS, TRENTON MICHAEL
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with MEDICAGO UNLEASH THE POWER OF PLANTS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Québec (Québec), CA
Québec (Québec), CA
Québec (Québec), CA
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Benjamin M. Cantor
Benjamin M. Cantor CANTOR COLBURN LLP20 CHURCH STREETFLOOR 22HARTFORD, CT 06103Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical and medicinal preparations and substances, namely, human vaccines, therapeutic proteins and antibodies for the treatment of infectious diseases, chronic diseases and cancer | ACTIVE | — |
| 040 | Manufacture of pharmaceuticals, pharmaceutical ingredients, human vaccines, therapeutic proteins and antibodies for others; Custom manufacturing of pharmaceuticals, pharmaceutical ingredients, human vaccines, therapeutic proteins and antibodies | ACTIVE | — |
| 042 | Research and development in the field of human vaccines, recombinant proteins and antibodies for therapeutic and prophylactic use; high-throughput vaccine engineering services; medical and scientific research services of proprietary recombinant protein platform technologies designed to lead to new human vaccines, therapeutic proteins and antibodies; product research and development and scientific research, all in the field of protein production using recombinant technologies through transient expression in plants; medical and scientific research services relating to infectious diseases; development of new products for others in the field of pharmaceuticals, pharmaceutical ingredients, human vaccines, therapeutic proteins and antibodies; medical and scientific research regarding clinical trial studies on new vaccine candidates; Medical information services, namely, providing medical research information to physicians, healthcare professionals and patients on the topics of diagnostic, prophylactic and therapeutic properties of vaccines, recombinant proteins and antibodies; On-line information services, namely, providing medical research information to physicians, healthcare professionals and patients on the topics of diagnostic, prophylactic and therapeutic properties of vaccines, recombinant proteins and antibodies | ACTIVE | — |
| 044 | Medical information services, namely, providing medical information to physicians, healthcare professionals and patients on the topics of health issues and maintaining awareness of one's health; Medical information services, namely, providing medical information to physicians, healthcare professionals and patients on the topics of diagnostic, prophylactic and therapeutic properties of vaccines, recombinant proteins and antibodies; On-line information services, namely, providing medical information to physicians, healthcare professionals and patients on the topics of health issues and maintaining awareness of one's health; On-line information services, namely, providing medical information to physicians, healthcare professionals and patients on the topics of diagnostic, prophylactic and therapeutic properties of vaccines, recombinant proteins and antibodies | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Medicago Inc.
- Other trademarks owned by Medicago Inc.
- Other trademarks owned by Medicago Inc.
- Other trademarks in Class 005
- Other trademarks in Class 040
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named MEDICAGO UNLEASH THE POWER OF PLANTS
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 11, 2022 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Oct 11, 2022 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jul 26, 2022 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jul 26, 2022 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jul 6, 2022 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jun 23, 2022 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jun 22, 2022 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Jun 22, 2022 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Jun 22, 2022 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Jun 22, 2022 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Jun 2, 2022 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jun 2, 2022 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jun 2, 2022 | ALIE | ASSIGNED TO LIE | — |
| May 25, 2022 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 26, 2021 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 26, 2021 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 26, 2021 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 17, 2021 | DOCK | ASSIGNED TO EXAMINER | — |
| Jul 11, 2021 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Apr 6, 2021 | NWAP | NEW APPLICATION ENTERED | — |